tailOred dRug repurposIng of dEcitabine in KRAS-dependeNt refracTory pAncreaTic cancEr
Status:
Recruiting
Trial end date:
2025-02-01
Target enrollment:
Participant gender:
Summary
The study is designed to assess the therapeutic efficacy of decitabine repurposing against
advanced, refractory, ductal adenocarcinoma (PDAC) with molecular transcriptional signatures
indicating dependency on the KRAS oncogene
Phase:
Phase 2
Details
Lead Sponsor:
Luca Cardone
Collaborators:
Anticancer Fund, Belgium Azienda Ospedaliera Universitaria Integrata Verona Catholic University of the Sacred Heart Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale San Raffaele University Hospital, Italy University of Pisa